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Centre, Winnipeg, Canada; and 6Department of Surgery, University of Manitoba, Winnipeg, CanadaIntroduction: Acute kidney injury (AKI) is a potentially fatal complication of cardiac surgery. The inability to
predict cardiac surgery-associated AKI is a major barrier to prevention and early treatment. Current clinical
risk models for the prediction of cardiac surgery-associated AKI are insufﬁcient, particularly in patients
with preexisting kidney dysfunction.
Methods: To identify intraoperative variables that might improve the performance of a validated clinical
risk score (Cleveland Clinic Score, CCS) for the prediction of cardiac surgery-associated AKI, we conducted
a prospective cohort study in 289 consecutive elective cardiac surgery patients at a tertiary care center. We
compared the area under the receiver operator characteristic curve (AUC) of a base model including only
the CCS with models containing additional selected intraoperative variables including mean arterial
pressure, hematocrit, duration of procedure, blood transfusions, and ﬂuid balance. AKI was deﬁned by the
Kidney Disease Improving Global Outcomes 2012 criteria.
Results: The CCS alone gave an AUC of 0.72 (95% conﬁdence interval, 0.62–0.82) for postoperative AKI.
Nadir intraoperative hematocrit was the only variable that improved AUC for postoperative AKI when
added to the CCS (AUC ¼ 0.78; 95% conﬁdence interval, 0.70–0.87; P ¼ 0.002). In the subcohort of patients
without preexisting chronic kidney disease (n ¼ 214), where the CCS underperformed (AUC, 0.60 [0.43–
0.76]), the improvement with the addition of nadir hematocrit was more marked (AUC, 0.74 [0.62–0.86]).
Other variables did not improve discrimination.
Discussion: Nadir intraoperative hematocrit is useful in improving discrimination of clinical risk scores for
AKI, and may provide a target for intervention.
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).A cute kidney injury (AKI) is an importantcomplication of cardiac surgery and is associated
with signiﬁcantly increased morbidity,1–4 mortal-
ity,1,2,4–10 and health care costs.5 AKI occurs in up to
18% of patients undergoing cardiac surgery, with 2%
of all patients requiring renal replacement therapy.4
Although overall mortality for cardiac surgery is
typically between 2% and 3%,6,11 this rate doubles
with even mild postoperative AKI, and approaches
60% for AKI severe enough to require dialysis.5–10,12 In
addition, cardiac surgery-associated AKI (CSA-AKI) isspondence: Claudio Rigatto, Department of Medicine and
ology, University of Manitoba, 2300 McPhillips Street, Room
, Winnipeg, Manitoba, R2V 3M3, Canada. E-mail: crigatto@
mb.ca
ved 27 July 2016; revised 11 October 2016; accepted 11
er 2016; published online 21 October 2016
International Reports (2016) -, -–-associated with increased rates of infection,13
dysfunction in multiple other organ systems,2–4,14
longer ICU and hospital length of stay,2 and long-
term kidney disease.1
CSA-AKI is believed to originate intraoperatively,15
the cumulative result of ischemic insults,15–19 sys-
temic inﬂammation,20–23 and oxidative stress,17,22,24,25
ultimately resulting in progression to tubular necro-
sis. Animal models consistently demonstrate the po-
tential to abrogate or prevent AKI with a variety of
pharmaceutical approaches targeting these mecha-
nisms,26–30 provided the treatment is instituted before
signiﬁcant tubular cell death occurs.15 In the context of
CSA-AKI, for example, the application of this early
treatment paradigm requires diagnosis and treatment of
AKI intraoperatively, at the time of the incipient
injury.31–34 Unfortunately, timely intraoperative diag-
nosis of AKI is not yet feasible. Serum creatinine, the1
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to reach diagnostic thresholds.34 Even novel urinary
biomarkers lack adequate discrimination to guide
therapy when measured intraoperatively.35
An alternative approach to “real-time” diagnosis is
to use clinical variables measured before or at the time
of surgery to predict risk of postoperative AKI. Pro-
vided the risk model is sufﬁciently accurate, such a
prediction tool could be used to guide the imple-
mentation of more intensive renoprotective efforts and
surveillance in patients at highest risk. Importantly,
better risk prediction could improve pretest proba-
bilities for novel diagnostic tests of CSA-AKI, thereby
improving the performance of early diagnostic
markers and possibly paving the way for more spe-
ciﬁc, targeted therapies. A number of predictive
models based on preoperative risk factors9,35–40 have
been developed for CSA-AKI. Of these, the Cleveland
Clinic Score (CCS, often called the Thakar score) is the
best validated and most predictive of these tools
(Table 1).41 Originally developed to predict renal
replacement therapy after cardiac surgery, the CCS has
since been validated for the prediction of less severe
CSA-AKI.36–38
Despite its usefulness, the CCS does not incorporate
potentially useful intraoperative information. The score
is also heavily inﬂuenced by preoperative kidney
dysfunction, and is less discriminatory in patients with
normal preoperative kidney function. We hypothe-
sized that the performance of the CCS could be
improved by the incorporation of easily measured
intraoperative variables capturing the aspects of ade-
quacy of organ perfusion, such as intraoperative blood
pressure, hematocrit, urine output, blood transfusion,
and ﬂuid administration.Table 1. Cleveland Clinic Score
Risk factor Points
Female gender 1
Congestive heart failure 1
Left ventricular ejection fraction <35% 1
Preoperative use of intra-aortic balloon pump 2
Chronic obstructive pulmonary disease 1
Insulin-requiring diabetes 1
Previous cardiac surgery 1
Emergency surgery 2
Surgery type:
Coronary artery bypass grafting only 0
Valve repair/replacement only 1
Coronary artery bypass grafting þ valve 2
Any other cardiac surgery 2
Preoperative creatinine:
107 to <186 mM (1.2 to <2.1 mg/dl) 2
$186 mM ($2.1 mg/dl) 5
Maximum score 17
2METHODS
The University of Manitoba Human Research Ethics
Board and the Saint Boniface General Hospital Research
Review Committee approved our research protocol, and
all patients provided informed consent.
Study Design
We employed an observational prospective cohort
design. All adult patients scheduled for elective cardiac
surgery at a tertiary care center (Saint Boniface General
Hospital, Winnipeg, Canada) were considered for in-
clusion. Patient recruitment occurred between June
2012 and July 2014. Exclusion criteria included
age < 18 years, chronic kidney disease of stage V or
greater (Modiﬁcation of Diet in Renal Disease estimated
glomerular ﬁltration rate < 15 ml/min per 1.73 m2),
currently on dialysis for any indication, previous
kidney transplant, or planned off-pump procedure.
Data Collection
Data were abstracted from patient charts as well as
from the Manitoba Cardiac Surgery Database for the
duration of hospital stay from time of entry to the
operating room to hospital discharge. All data were
collected according to routine clinical practice. Baseline
data and demographics were recorded during the pre-
surgical clinic visit and/or on admission to hospital.
Mean arterial pressure (MAP) was monitored via an
arterial catheter and recorded by the anesthetist at 5-
minute intervals. Data on hematocrit from intra-
operative arterial blood gas panels were abstracted at
the following times: (i) at time of arterial line place-
ment, (ii) on initiation of cardiopulmonary bypass
(CPB), (iii) 1 hour after the commencement of CPB, and
(iv) at arrival to postoperative ICU. Surgery duration
was recorded in the intraoperative record. Pump time
and cross clamp time were recorded in the perfusion
record. Use of blood products was recorded in a
transfusion log. Volume inputs were recorded by the
anesthesiologist and perfusionist. Urine outputs for the
entire operative period as well as outputs speciﬁc to the
period while on CPB were recorded intraoperatively by
nursing staff. Creatinine was measured at arrival to ICU
and in the morning of each postoperative day, along
with other routine bloodwork.
Primary Exposure Variables of Interest
The CCS, a well-validated AKI risk score, was calcu-
lated based on the relevant preoperative variables for
each patient (Table 1). Nadir hematocrit was deﬁned as
the lowest of the 4 hematocrits measured during the
operation at the time points described above. Average
MAP was deﬁned as the average of all MAP readings
recorded during surgery. The total number ofKidney International Reports (2016) -, -–-
Figure 1. STROBE diagram of cohort. RRT, renal replacement
therapy.
J Crosina et al.: Intraoperative Prediction of CSA-AKI CLINICAL RESEARCHtransfusions given during surgery and pump time were
abstracted from the perfusionists’ records. Average
hourly urine output during surgery was calculated by
dividing the total intraoperative urine volume by the
duration of the surgery.
Primary Outcome
AKI was deﬁned according to the 2012 KDIGO guide-
lines (rise in serum creatinine $ 26.5 mM within
48 hours, or serum creatinine $ 150% baseline within
7 days). We did not include the oliguria criteria in our
deﬁnition of CSA-AKI. Urine output after cardiac sur-
gery is a reﬂection of many parameters apart from renal
damage (e.g., ﬂuid balance, diuretic use, altered renin-
angiotensin-aldosterone axis), and so is generally
considered to be unhelpful in identifying CSA-AKI
after cardiac surgery.51,52
Statistical Analyses
SAS version 9.3 was used for all statistical analyses.
Main Analysis
From a clinical perspective, the added complexity of
monitoring and incorporating intraoperative informa-
tion can only be justiﬁed if that information signiﬁ-
cantly improves AKI prediction beyond current
prediction models. The CCS is a widely used and well-
validated clinical AKI prediction model, and was used
as our reference model in all analyses. We ﬁrst gener-
ated a logistic regression model incorporating only the
CCS. We then sequentially added candidate intra-
operative variables to the base model. Variables were
retained in the model only if they signiﬁcantly
improved the c-statistic of the base CCS model.
Although the c-statistic was our primary metric of
model performance, we also examined alternative
measures of model discrimination (integrated discrim-
ination improvement), as well as model calibration
(Hosmer-Lemeshow) and reclassiﬁcation in the ﬁnal
models.53,54
Secondary Analysis
The CCS is heavily inﬂuenced by preoperative kidney
dysfunction, and may perform less well in patients
without prior kidney dysfunction. We therefore
examined the performance of the CCS, with and
without the addition of preoperative variables, in a
subcohort of individuals without kidney dysfunction
at baseline, deﬁned as an estimated glomerular ﬁltration
rate $ 60 ml/min.
Sensitivity Analyses
We conducted several sensitivity analyses to explore
whether different thresholds applied to each ofKidney International Reports (2016) -, -–-the main variables tested might alter the models
(Supplementary Table S1).
RESULTS
Study Population
Demographic and operative data for the prospective
cohort of 289 consecutive adult elective cardiac surgery
patients are presented in Figure 1 and Table 2. All
patients were followed until discharge from hospital.
The cohort was predominantly male, with an average
age of 66 years. As expected, risk factors for heart
disease were prevalent, including hypertension (71%),
diabetes mellitus (32%), and history of myocardial
infarction (36%). New CSA-AKI occurred in 12%
(n ¼ 35) of the study cohort overall, and in 7.5%
(n ¼ 16) in the subgroup without prior kidney
dysfunction. Patients who developed AKI as deﬁned
by the 2012 KDIGO criteria had lower preoperative
Modiﬁcation of Diet in Renal Disease estimated
glomerular ﬁltration rate and were more likely to be
diabetic and have a history of congestive heart failure.
Not surprisingly, those who developed AKI were sicker
than those who did not, with a higher score on the
European System for Cardiac Operative Risk Evaluation
(euroSCORE II; 4.0 vs. 2.6 in AKI vs. non-AKI,
respectively). The euroSCORE II is a widely used pre-
dictive model for mortality after cardiac surgery and is
based on preoperative health status and type of sur-
gery.42 Similar trends in demographic and operative
variables were observed in the subgroup of patients
without prior kidney dysfunction (Table 3).
Patients who developed CSA-AKI had a higher mean
CCS of 3.3, compared with a mean of 1.8 in those who
did not. This is in keeping with the previous literature
for elective (nonemergent) cardiac surgery cohorts.9,37–39
Intraoperative Variables
We examined the univariate association between
selected intraoperative variables and AKI status
(Table 4). CPB time was longer in those developing AKI
(125 vs. 107 minutes); however, intraoperative urine3
Table 2. Selected baseline characteristics of the full cohort
Total Non-AKI AKI P
N 289 254 35
Age (yr) 66 (10) 66 (10) 69 (11) 0.05*
Female (%) 24 23 31 0.3
Previous CABG (%) 3.1 2.8 5.7 0.3
Previous cardiac intervention (%) 10 10 14 0.4
Comorbid conditions (%)
Diabetes mellitus 32 29 57 0.002*
COPD 7.2 7.5 5.7 1.0
Heart failure 9.3 7.5 23 0.008*
Myocardial infarction 36 37 31 0.6
Arrhythmia 19 17 31 0.06
Hypertension 71 70 83 0.1
ICD 2.4 2.0 5.7 0.2
Peripheral artery disease 7.9 7.1 14 0.2
Cerebrovascular accident 5.9 5.1 11 0.1
Transient ischemic attack 4.1 4.3 2.9 1.0
Type of surgery (% CABG only) 61 63 54 0.4
EuroSCORE II 2.7 (3.8) 2.5 (3.8) 4.0 (3.3) 0.03*
CCS 2.0 (1.7) 1.8 (1.5) 3.3 (2.1) <0.001
Presurgery kidney function
Baseline serum creatinine (mmol/l) 92 (33) 89 (27) 120 (52) <0.0001*
eGFR (ml/min per 1.73 m2) 78 (23) 81 (22) 60 (21) <0.0001*
CABG, coronary artery bypass grafting; CCS, Cleveland Clinic Score; COPD, chronic
obstructive pulmonary disease; eGFR, estimated glomerular ﬁltration rate; ICD,
implantable cardioverter deﬁbrillator.
*Significant at P < 0.05.
Table 4. Association between selected intraoperative variables and
AKI
Intraoperative variable Overall Non-AKI AKI P
Pump time (min) 109 (49) 107 (48) 125 (54) 0.04
Nadir hematocrit 0.28 (0.04) 0.25 (0.03) <0.001
Total urine output in OR (ml) 783 (471) 794 (481) 699 (382) 0.3
Average MAP (mm Hg) 71.2 (4.6) 71.2 (4.6) 71.3 (4.9) 0.9
Total crystalloid in OR (ml) 4698 (1294) 4641 (1264) 5113 (1424) 0.04
Total PRBC in OR (units) 0.71 (1.57) 0.60 (1.44) 1.51 (2.13) 0.001
AKI, acute kidney injury; MAP, mean arterial pressure; OR, operating room; PRBC,
packed red blood cells.
CLINICAL RESEARCH J Crosina et al.: Intraoperative Prediction of CSA-AKIoutput and MAP were similar in both groups. Patients
with AKI exhibited a lower nadir hematocrit
(deﬁned as the lowest hematocrit observed during
intraoperative sampling) than those without AKITable 3. Selected baseline characteristics of patients without prior
CKD
Total Non-AKI AKI P
No. 214 198 16
Age (yr) 65 (10) 65 (910) 69 (13) 0.04*
Female (%) 24 23 38 0.2
Previous CABG (%) 2.4 2.5 0.0 1.0
Previous cardiac intervention (%) 8.5 8.2 12 0.6
Comorbid conditions (%)
Diabetes mellitus 28 27 38 0.4
COPD 8.4 8.1 12 0.6
Heart failure 5.6 5.6 6.3 1.0
Myocardial infarction 34 35 25 0.4
Arrhythmia 17 15 31 0.2
Hypertension 67 67 69 0.9
ICD 1.4 1.0 6.3 0.2
Peripheral artery disease 6.1 6.1 6.3 1.0
Cerebrovascular accident 2.8 2.5 6.3 0.4
Transient ischemic attack 3.8 3.6 6.3 0.5
Type of surgery (% CABG only) 63 63 56 0.6
EuroSCORE II 2.0 (2.5) 2.0 (2.5) 3.0 (2.9) 0.1
Thakar score 1.3 (1.1) 1.3 (1.1) 1.8 (1.4) 0.2
Presurgery kidney function
Baseline serum creatinine (mmol/l) 78 (14) 78 (14) 82 (14) 0.4
eGFR (ml/min per 1.73 m2) 88 (17) 89 (17) 79 (11) 0.02*
CABG, coronary artery bypass grafting; CKD, chronic kidney disease; COPD, chronic
obstructive pulmonary disease; eGFR, estimated glomerular ﬁltration rate; ICD,
implantable cardioverter deﬁbrillator.
*Significant at P < 0.05.
4(0.25  0.03 vs. 0.28  0.04; P < 0.001). Total crys-
talloid administered was slightly greater in patients
who developed AKI (5113  1424 vs. 4641  1264;
P ¼ 0.04), as was the total number of units of packed
red blood cells transfused (1.51  2.13 vs. 0.60  1.44;
P ¼ 0.001). Results were similar among patients
without CKD before surgery (Table 5).
Effect of Intraoperative Variables on Prediction
The CCS alone showed reasonable discrimination for
AKI (c-statistic 0.72 [95% conﬁdence interval, 0.62–
0.82]; Table 6).
Nadir hematocrit was the only variable conferring
signiﬁcant improvement in discrimination (Figure 2,
c-statistic 0.78 [0.70–0.87], P ¼ 0.002, compared with
CCS alone). This model had acceptable calibration
(Supplementary Table S1), and led to signiﬁcant inte-
grated discrimination improvement relative to the
CCS alone. The category-free net reclassiﬁcation
improvement was 58.8% (24.7%–92.8%), P ¼ 0.001,
indicating signiﬁcant overall improvement in risk
classiﬁcation.
In contrast, duration of bypass, MAP, transfusion,
and intraoperative urine output did not improve AKI
discrimination beyond that achieved by the CCS alone.
In a secondary analysis, we restricted our analysis to
the subcohort of patients without known kidney dis-
ease before surgery (n ¼ 214; Table 7 and Figure 3).
Discrimination of the CCS alone in this subgroup was
poor (0.60 [0.43–0.76]). Nadir hematocrit signiﬁcantly
improved model discrimination (0.74 [0.62–0.86]). None
of the other variables signiﬁcantly improved discrimi-
nation of the CCS.Table 5. Association between selected intraoperative variables and
AKI in patients without prior CKD
Intraoperative variable Total Non-AKI AKI P
Pump time (min) 106 (44) 105 (43) 126 (52) 0.102
Nadir hematocrit 0.29 (0.04) 0.29 (0.04) 0.25 (0.04) 0.001
Total urine output in OR (ml) 808 (484) 808 (493) 804 (371) 0.726
Average MAP (mm Hg) 71.1 (4.5) 71.2 (4.6) 70.5 (4.3) 0.661
Total crystalloid in OR (ml) 4592 (1247) 4542 (1227) 5217 (1368) 0.044
Total PRBC in OR (units) 0.61 (1.53) 0.53 (1.46) 1.69 (1.99) <0.001
AKI, acute kidney injury; CKD, chronic kidney disease; MAP, mean arterial pressure; OR,
operating room; PRBC, packed red blood cells.
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Table 6. Change in model discrimination for AKI with the addition of
selected intraoperative variables to the Cleveland Clinic Score (CCS)
alone: full cohort (n ¼ 289)
Model
Area under the
ROC curve 95% CI
P value (compared with
Thakar only)
CCS (base model) 0.72 0.62–0.82 Reference model
CCS þ Pump Time 0.73 0.62–0.83 0.4
CCS þ Total Volume Input 0.73 0.62–0.83 0.5
CCS þ Red Blood Cell
Transfusion
0.75 0.65–0.85 0.07
CCS D Hematocrit Nadir 0.78 0.70--0.87 0.002
CCS þ Average MAP 0.72 0.62–0.83 0.8
CCS þ Average Urine
Output/h in OR
0.73 0.63–0.83 0.4
AKI, acute kidney injury; CI, conﬁdence interval; MAP, mean arterial pressure; OR,
operating room; ROC, receiver operator characteristic.
Table 7. Change in model discrimination for AKI with the addition of
selected intraoperative variables to the Cleveland Clinic Score
(CCS): subcohort without prior CKD (n ¼ 214)
Model
Area under the
ROC curve 95% CI
P value (compared with
Thakar alone)
CCS (base model) 0.60 0.43–0.76 Reference
CCS þ Pump Time 0.61 0.46–0.76 0.7
CCS þ Total Volume Input 0.65 0.49–0.81 0.3
CCS þ Red Blood Cell
Transfusion
0.68 0.51–0.85 0.07
CCS D Hematocrit Nadir 0.74 0.62--0.86 0.01
CCS þ Average MAP 0.61 0.45–0.76 0.8
CCS þ Average Urine
Output/h in OR
0.62 0.47–0.77 0.4
Pump Time: total duration of CPB. Total Volume Input: ﬂuid volume given during OR time.
Red Blood Cell Transfusion: whether or not transfusion of RBC was given, regardless of
amount. Hematocrit Nadir: lowest intraoperative hematocrit. Average MAP: mean of
intraoperative MAP measurements. Average Urine Output/h in OR: total urine output
measured during OR/duration of OR.
AKI, acute kidney injury; CI, conﬁdence interval; CKD, chronic kidney disease; CPB,
cardiopulmonary bypass; MAP, mean arterial pressure; OR, operating room; RBC, red
blood cell; ROC, receiver operator characteristic.
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In a set of sensitivity analyses, alternative methods of
deﬁning the primary intraoperative exposure variables
were explored (SDC, Table 1). As with the main anal-
ysis, nadir hematocrit remained the most predictive
intraoperative variable. Hematocrit at the start of CPB
or at 1 hour into CPB also appeared to improve
discrimination, but to a lesser extent than nadir he-
matocrit. Of note, hematocrit at arrival to the operating
room did not improve prediction. Prolonged hypoten-
sion, speciﬁcally a MAP < 55 mm Hg for more than 25
minutes, appeared to confer an additional small incre-
ment in discrimination to the base CCS model. The ef-
fects of both hematocrit and prolonged hypotension
were also seen in the subcohort without kidney disease
preoperatively.0.00
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Thakar Score + Hematocrit Nadir Model:  AUC = 0.783 (0.696 – 0.869)
Thakar Score Only Model:  AUC = 0.721 (0.619 – 0.824)
IDI: 2.1% (–0.4% to 4.5%) - P=0.104
cfNRI: 58.8% (24.7% to 92.8%) - P=0.001
HL Test: P=0.539
Figure 2. Comparison of area under the curve (AUC) for the receiver
operator characteristic curves for the Cleveland Clinic Score (Tha-
kar score) only and the Cleveland Clinic Score (Thakar score) þ
hematocrit nadir in the full cohort (n ¼ 289). cfNRI, category-free net
reclassiﬁcation index; HL, Hosmer Lemeshow test; IDI, integrated
discrimination improvement.
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In our study of 289 adults undergoing cardiac surgery,
we found that the addition of intraoperative nadir
hematocrit to a well-established preoperative risk score
signiﬁcantly improved the prediction of new post-
operative AKI. The improvement was even more pro-
nounced in patients without CKD, a subgroup where
the CCS underperforms. In contrast, intraoperative
MAP, crystalloid and blood product administration,
and urine output did not improve the prediction of
AKI.
Our main ﬁnding that measurement of nadir he-
matocrit improves the prediction of CSA-AKI is in line
with recent reports showing that nadir hemoglobin and
anemia are important predictors of CSA-AKI.18,43–45
Prior studies have shown an inverse correlation be-
tween nadir intraoperative hematocrit and risk of CSA-
AKI in univariate analyses. Our study provides a more
robust conﬁrmation of this ﬁnding by demonstrating
the additive value of nadir hematocrit in a multivariate
prediction model. In contrast to previous studies,44,45
the addition of hematocrit at arrival to the operating
room to the CCS did not improve the prediction of AKI
in this analysis. This suggests that nadir intraoperative
hematocrit is not just a surrogate for preoperative
anemia, but adds important new information about AKI
risk during the surgical procedure.
The data from this study conﬁrm that the CCS
underperformed in patients without preexisting kidney
disease. As the CCS weighs the presence or absence of
baseline kidney dysfunction quite heavily, awarding 2
points for a serum creatinine of 107 to <186 mM (1.2
to<2.1 mg/dl) and 5 points for a serum creatinine$ 186
mM (2.1 mg/dl), this observation is not unexpected.5
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Thakar Score + Hematocrit Nadir Model:  AUC = 0.741 (0.618 – 0.865)
Thakar Score Only Model:  AUC = 0.596 (0.433 – 0.759)
IDI: 3.7% (0.6% to 6.7%) - P=0.019
cfNRI: 100.9% (60.5% to 141.2%) - P<0.001
HL Test: P=0.742
Figure 3. Comparison of receiver operator characteristic curves for
the Cleveland Clinic (Thakar) score only and the Cleveland Clinic
(Thakar) score þ hematocrit nadir in the subset of patients without
kidney dysfunction at baseline (n ¼ 214). AUC, area under the curve;
cfNRI, category-free net reclassiﬁcation index; HL, Hosmer Leme-
show test; IDI, integrated discrimination improvement.
CLINICAL RESEARCH J Crosina et al.: Intraoperative Prediction of CSA-AKIImportantly, nadir hematocrit improved discrimination
signiﬁcantly in this subcohort of patients without pre-
existing kidney disease, restoring discrimination of the
model to a clinically adequate level and suggesting that
measurement of nadir hematocrit might be especially
useful in patients without CKD before surgery.
The mechanisms by which changes in hematocrit
inﬂuence risk of AKI have not been fully elucidated.18
Both direct and indirect effects have been suggested. It
is plausible that a low hematocrit decreases oxygen
delivery to the kidney, exacerbating renal hypoxia and
contributing to injury.43 Alternatively, hematocrit may
be a marker for ﬂuid shifts, hemodilution,46 operative
blood loss,47 need for transfusions48, or hemolysis,19
each of which may inﬂuence the risk of ischemic
and/or hypoxic renal injury. Because hemodilution and
blood loss were indirectly evaluated by ﬂuid balance
and blood transfusion, respectively, and were not
found to be signiﬁcant, our results favor the hypothesis
that hemolysis, with release of free hemoglobin, might
be the key mediator of the relationship between he-
matocrit and AKI. Measurement of free hemoglobin
perioperatively would have elucidated this possibility,
but was not possible in this study. Finally, hematocrit
and its correlates are potentially modiﬁable, and
represent attractive targets for intervention in future
trials of AKI prevention.
We did not ﬁnd an association between mean
intraoperative MAP and AKI, an observation
congruent with several other studies. MAP measured
in the OR may not adequately reﬂect organ perfusion,
because most organs, including the kidney, possess a
signiﬁcant degree of autoregulation that maintains
perfusion until perfusion pressure drops below some6threshold. In the sensitivity analyses, we found that a
threshold duration and severity of hypotension,
deﬁned as a sustained 25 minutes of MAP below
55 mm Hg, were associated with a statistically signiﬁ-
cant, albeit small, improvement in CSA-AKI prediction
compared with the CCS alone. Although this ﬁnding
is biologically plausible, it must be interpreted
cautiously, as this observation was the result of a post
hoc analysis involving multiple statistical tests. The
risk of a spurious ﬁnding is therefore high. Moreover,
several other studies have looked for and failed to ﬁnd
a similar blood pressure and/or duration threshold
predictive of AKI.43,49,50
Volume of crystalloid input was not predictive of
CSA-AKI in our study. Crystalloid volume plausibly
contributes to hemodilution and may thus be
confounded with and incorporated into the hematocrit
effect. Alternatively, in our cohort of stable elective
cardiac surgery patients, the observed variation in ﬂuid
administration between patients may have been too
small to discern an impact on AKI risk. The difference
in mean crystalloid administered to those who devel-
oped AKI and those who did not was less than 500 ml
(Tables 4 and 5), which after redistribution would not
cause large differences in intravascular volume or he-
matocrit. These same 2 reasons (i.e., confounding and
lack of variation) could also explain why signiﬁcant
effects of blood transfusion on CSA-AKI were not
observed in our study.
Our results have potential clinical and research im-
plications. In the context of a growing body of literature
highlighting the importance of intraoperative anemia,
our ﬁndings support intraoperative monitoring of he-
matocrit, in addition to the CCS, as a feasible, useful, and
economical way of improving risk prediction for AKI
after surgery, particularly in patients without preexist-
ing kidney disease. More accurate AKI risk classiﬁcation
during surgery could help inform subsequent care, in
particular decisions regarding volume loading, di-
uretics, and transfusions in the immediate postoperative
period. Identiﬁcation of more targeted therapies for AKI
prevention will rely in part on future elucidation of the
main causal mechanisms underlying the association be-
tween low hematocrit and AKI. As discussed above, if
the link is causal, aggressive correction of lowhematocrit
could improve risk AKI and clinical trials comparing
higher versus lower transfusion thresholds based on
nadir hematocrit will be needed to answer this question.
On the other hand, if the link is mediated via the
mechanism of hemolysis, as indirectly suggested by our
data, then clinical trials of strategies to limit hemolysis or
abrogate the toxic effects of free hemoglobin on the
kidney should be prioritized.Kidney International Reports (2016) -, -–-
J Crosina et al.: Intraoperative Prediction of CSA-AKI CLINICAL RESEARCHOur study has several strengths. Our analysis pro-
spectively examined intraoperative variables plausibly
associated with renal ischemia reperfusion or hypoxia.
Our main ﬁndings are biologically plausible, congruent
with emerging literature, and can directly inform
future research. Moreover, intraoperative hematocrit is
easily and in some cases routinely measured, facili-
tating knowledge translation and clinical application.
Our study also has some limitations. The sample size
was small and our study may have lacked the power to
detect all associations between with intraoperative
variables and AKI. Our study was not powered to
examine hard outcomes such as dialysis or death.
Finally, our study population comprised a relatively
low risk cohort of elective cardiac surgery patients,
with low to intermediate mean CCS. Generalizing our
results to higher risk cardiac surgery patients may not
be appropriate.
In conclusion, the addition of nadir hematocrit to a
well-established preoperative risk score improved the
prediction of AKI, especially in patients without pre-
operative kidney disease. In contrast, intraoperative
MAP, crystalloid and blood product administration,
and urine output did not improve the AKI prediction.
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